Products & Services · Total revenues
TEPEZZA — Total revenues
Amgen TEPEZZA — Total revenues decreased by 94.3% to $490M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 94.0%, from $8.15B to $490M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market penetration or successful clinical adoption of the therapy, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross revenue generated from the sales of a specific therapeutic product line within th...
Peer comparison
Comparable to product-specific revenue reporting for flagship therapeutics at other large-cap biotechnology and pharmaceutical companies.
Metric ID:
amgn_segment_tepezza_total_revenuesHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $0 | $6.71B | $0 | $6.85B | $0 | $6.24B | $0 | $6.59B | $0 | $6.65B | $0 | $6.84B | $0 | $6.11B | $0 | $6.99B | $0 | $6.9B | $0 | $8.2B | $448M | $7.45B | $424M | $8.39B | $479M | $8.5B | $488M | $9.09B | $460M | $8.15B | $381M | $9.18B | $505M | $9.56B | $560M | $9.87B | $457M | $8.62B | $490M |
| QoQ Change | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — | -94.5% | >999% | -94.3% | >999% | -94.3% | >999% | -94.3% | >999% | -94.9% | >999% | -95.3% | >999% | -94.5% | >999% | -94.1% | >999% | -95.4% | >999% | -94.3% |
| YoY Change | — | — | — | — | — | — | — | — | +1.0% | -100.0% | -0.8% | -100.0% | -0.1% | -100.0% | -2.1% | -100.0% | +5.9% | -100.0% | +3.8% | -100.0% | +19.8% | -93.4% | +22.0% | -93.1% | +20.1% | -93.1% | +23.2% | -92.9% | +10.9% | -94.4% | +9.4% | -94.9% | +9.4% | -94.0% | +12.4% | -93.4% | +8.6% | -95.0% | +5.8% | -94.0% |
Range$0 – $9.87B
CAGR-23.3%
Avg YoY Growth-43.4%
Median YoY Growth-47.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's tepezza — total revenues?
- Amgen (AMGN) reported tepezza — total revenues of $490M in Q1 2026.
- How has Amgen's tepezza — total revenues changed year-over-year?
- Amgen's tepezza — total revenues decreased by 94.0% year-over-year, from $8.15B to $490M.
- What does tepezza — total revenues mean?
- The total sales revenue generated by a specific therapeutic product line.